Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 4/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | VNN1 | O95497 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | CKS1B | P61024 | 1/20 | 0.31 |
| ▸ | SKP1 | P63208 | 1/20 | 0.31 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL149123 | 1.00 | EIF2AK4 (0.35) | EIF2AK4GPR119JAK3BTKACACB | |
| SCHEMBL149122 | 1.00 | EIF2AK4 (0.35) | EIF2AK4GPR119JAK3BTKACACB | |
| SCHEMBL148610 | 0.90 | GPR119 (0.39) | GPR119 | |
| SCHEMBL151482 | 0.87 | GPR119 (0.34) | EIF2AK4GPR119KCNH2 | |
| SCHEMBL151484 | 0.87 | GPR119 (0.34) | EIF2AK4GPR119KCNH2 | |
| SCHEMBL151483 | 0.87 | GPR119 (0.34) | EIF2AK4GPR119KCNH2 | |
| SCHEMBL148829 | 0.85 | GPR119 (0.35) | EIF2AK4GPR119ACACBKCNH2 | |
| SCHEMBL149426 | 0.83 | DPP4 (0.43) | GPR119KCNH2HCRTR1HCRTR2 | |
| SCHEMBL149427 | 0.83 | DPP4 (0.43) | GPR119KCNH2HCRTR1HCRTR2 | |
| SCHEMBL121107 | 0.83 | DPP4 (0.43) | GPR119KCNH2HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FFAR2, GPBAR1 | EIF2AK4 960/4885GPR119 1/4885JAK3 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.